Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial

Currently, there are no randomized trials on the effect of antiangiogenic therapy in patients with esophageal squamous cell carcinoma (ESCC). The following study investigated the efficacy and safety of anlotinib in patients with advanced ESCC who were previously treated with chemotherapy.

[1]  Y. Ba,et al.  Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. , 2020, The Lancet. Oncology.

[2]  Sung-Bae Kim,et al.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[3]  Sung-Bae Kim,et al.  Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. , 2019, Journal of Clinical Oncology.

[4]  F. Du,et al.  Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[5]  Ying Cheng,et al.  Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial , 2018, JAMA oncology.

[6]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[7]  H. Hurwitz,et al.  Combinations of Bevacizumab With Cancer Immunotherapy , 2018, Cancer journal.

[8]  Yahiya Y. Syed.  Anlotinib: First Global Approval , 2018, Drugs.

[9]  F. Du,et al.  Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma , 2018, Clinical Cancer Research.

[10]  Ying Cheng,et al.  Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) , 2018, British Journal of Cancer.

[11]  P. Lu,et al.  Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single‐Arm, Multicenter Phase 2 Study , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Charles R. Thomas,et al.  The Global Burden of Esophageal Cancer: A Disability-Adjusted Life-Year Approach , 2016, World Journal of Surgery.

[13]  G. Keating.  Bevacizumab: A Review of Its Use in Advanced Cancer , 2014, Drugs.

[14]  D. Ferry,et al.  Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. , 2014, The Lancet. Oncology.

[15]  Michael W Sill,et al.  Improved survival with bevacizumab in advanced cervical cancer. , 2014, The New England journal of medicine.

[16]  Jie He,et al.  A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy , 2013, Medical Oncology.

[17]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Zhong,et al.  Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Yamana,et al.  Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). , 2001, Japanese journal of clinical oncology.